TRAW · Traws Pharma, Inc.
$0.57
-0.03 (-4.83%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern through the one-year period after the date that the financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$8.78M
Shares
15.37M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.79M
+1134.5%
FY2025
Net Income
$9.17M
+105.5%
FY2025
Operating Margin
-640.68%
+62356.7pp
FY2025
Diluted EPS
$0.82
+102.3%
FY2025
Operating Cash Flow
-$18.19M
+39%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $2.79M | $226K | $226K | $226K | $226K | $231K | $2.18M | $1.23M | $787K | $5.55M | $11.46M | $800K | $4.75M | $46.19M | $1.49M | |
| $13.36M | $12.14M | $12.85M | $11.43M | $11.41M | $7.3M | $16.9M | $15.54M | $16.92M | $19.12M | $20.07M | $25.9M | $49.43M | $50.18M | $52.76M | $22.62M | |
| $9.59M | $8.52M | $12.29M | $9.09M | $8.45M | $9.43M | $8.33M | $8.35M | $7.59M | $7.41M | $9.18M | $9.53M | $15.12M | $16.79M | $15.71M | $6.44M | |
| $144K | $58K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $61K | $12K | $16K | $14K | $14K | $13K | $14K | $55K | $88K | $96K | $150K | $434K | $446K | $319K | $316K | |
| $21.54M | $20.67M | $142.6M | $20.52M | $19.85M | $16.72M | $25.22M | $23.88M | $24.51M | $26.52M | $29.25M | $35.43M | $64.54M | $66.98M | $68.47M | $29.06M | |
| -$21.54M | -$17.88M | -$142.37M | -$20.3M | -$19.63M | -$16.5M | -$24.99M | -$21.7M | -$23.28M | -$25.74M | -$23.7M | -$23.97M | -$63.74M | -$62.22M | -$22.28M | -$27.57M | |
| — | -640.68% | -62997.35% | -8981.42% | -8684.51% | -7299.12% | -10819.48% | -994% | -1895.93% | -3270.27% | -427.39% | -209.25% | -7968% | -1309.11% | -48.23% | -1854.27% | |
| — | -$17.81M | -$142.36M | -$20.28M | -$19.61M | -$16.48M | -$24.98M | -$21.69M | -$23.23M | -$25.65M | -$23.61M | -$23.82M | -$63.31M | -$61.78M | -$21.96M | -$27.26M | |
| — | — | — | — | — | — | — | — | — | — | — | — | $2000 | $4000 | $8.61M | $19K | |
| — | $455K | $510K | $1.39M | $651K | — | — | — | — | — | — | — | — | — | — | — | |
| $14K | $478K | $289K | $1.35M | $663K | $12K | $48K | $143K | $1.15M | $30K | $62K | -$35K | -$52K | $63K | $608K | $11K | |
| — | $9.17M | -$166.53M | -$18.95M | -$18.96M | -$16.16M | -$25.15M | -$21.49M | -$20.53M | -$24.08M | -$19.65M | -$24.01M | -$63.78M | -$62.12M | -$29.91M | -$26.29M | |
| — | — | — | — | — | — | $4000 | $10K | -$124K | $13K | $14K | $16K | $19K | $435K | — | — | |
| -$21.57M | $9.17M | -$166.52M | -$18.95M | -$18.96M | -$16.16M | -$25.16M | -$21.5M | -$20.57M | -$24.09M | -$19.67M | -$23.98M | -$63.68M | -$62.54M | -$29.91M | -$26.29M | |
| — | 328.67% | -73682.74% | -8384.07% | -8391.15% | -7151.77% | -10890.48% | -985.02% | -1675.33% | -3061.25% | -354.62% | -209.31% | -7960.25% | -1315.86% | -64.76% | -1768.26% | |
| — | — | — | — | — | — | — | — | $163K | — | — | -$44K | -$113K | -$13K | — | — | |
| -$15.9M | $6.87M | -$54.67M | -$18.95M | — | — | — | — | — | — | — | — | -$63.68M | -$64.86M | -$33.87M | -$30.31M | |
| -$21.58M | $9.22M | -$166.54M | -$18.94M | — | — | — | -$21.51M | -$20.59M | -$24.06M | -$19.68M | -$23.99M | -$63.7M | -$62.56M | -$29.91M | -$26.29M | |
| USD/shares | — | $0.83 | -$35.21 | -$22.57 | -$22.75 | -$24.00 | -$54.25 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | $0.82 | -$35.21 | -$22.57 | -$22.75 | -$24.00 | -$54.25 | — | — | — | — | — | — | — | — | — |
| shares | — | 8.23M | 1.55M | 839.55K | 836.33K | 673.29K | 464.1K | 38.36K | 11K | 1600.0587 | 11.8K | 6063.936 | 57.74K | 28.25K | 5885.0347 | 5699.7413 |
| shares | — | 8.38M | 1.55M | 839.55K | 836.33K | 673.29K | 464.1K | 38.36K | 11K | 1600.0587 | 11.8K | 6063.936 | 57.74K | 28.25K | 5885.0347 | 5699.7413 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.62×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.97×
Peer medians compare against the 192 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | $2,790,000 | $226,000 | $226,000 |
Key facts
CIK
1130598
CUSIP
68232V884
13F (30d)
39 filings
38 filers
Visit website
Investor relations